Corbus Pharmaceuticals Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | — | $0 | $881,705 |
| Research and development | $70.1M | $32.2M | $31.2M | $16.1M | $36.4M |
| Operating expenses | $85.3M | $48.7M | $45.1M | $39.8M | $56.9M |
| Operating income | -$85.3M | -$48.7M | -$45.1M | -$39.8M | -$56.0M |
| Interest expense | $0 | $1.9M | $3.9M | — | — |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$78.5M | -$40.2M | -$44.6M | -$42.3M | -$45.6M |
| Balance Sheet | |||||
| Cash and equivalents | $28.5M | $17.2M | $13.7M | $17.0M | $25.0M |
| Current assets | $167.0M | $153.0M | $23.5M | $60.2M | $100.2M |
| Total assets | $168.2M | $155.9M | $28.3M | $66.3M | $107.7M |
| Current liabilities | $20.7M | $11.8M | $31.9M | $12.6M | $17.0M |
| Total liabilities | $20.7M | $13.5M | $35.2M | $33.3M | $38.6M |
| Total debt | — | $0 | $15.9M | $18.8M | $18.7M |
| Stockholders' equity | $147.5M | $142.4M | -$6.9M | $33.0M | $69.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$64.5M | -$41.8M | -$36.1M | -$37.5M | -$48.2M |
| Depreciation and amortization | $200,000 | $600,000 | $600,000 | $763,000 | $1.0M |
| Stock-based compensation | $6.3M | $6.1M | $3.5M | $5.7M | $9.5M |
| Capital expenditure | $7,000 | $0 | $0 | $13,449 | $54,172 |
| Free cash flow | -$64.5M | -$41.8M | -$36.1M | -$37.6M | -$48.2M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 18.5M · Free float 83.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.